Refractory cytopenia with multilineage dysplasia
Information
- Disease name
- Refractory cytopenia with multilineage dysplasia
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02566304 | Active, not recruiting | Phase 2 | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | November 13, 2015 | February 13, 2024 |
| NCT00008177 | Completed | Phase 1 | Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | July 27, 1999 | December 15, 2010 |
| NCT00104962 | Completed | Phase 1 | Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes | March 2005 | June 2009 |
| NCT00305773 | Completed | Phase 2 | Vorinostat in Treating Patients With Acute Myeloid Leukemia | January 2006 | January 2010 |
| NCT00397813 | Completed | Phase 2 | Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders | January 2006 | March 2018 |
| NCT00005845 | Completed | Phase 1 | Tipifarnib in Treating Patients With Myelodysplastic Syndromes | June 2002 | |
| NCT00462605 | Completed | Phase 2 | MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia | April 2007 | March 2011 |
| NCT01165996 | Completed | Phase 1/Phase 2 | Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome | July 2010 | August 2012 |
| NCT01789255 | Completed | Phase 2 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | June 2013 | March 2014 |
| NCT00988715 | Completed | Phase 1 | Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | April 21, 2010 | |
| NCT01012492 | Completed | Phase 2 | Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT | November 2009 | January 2013 |
| NCT00589316 | Terminated | Phase 1 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome | October 5, 2007 | October 1, 2021 |
| NCT00119366 | Terminated | Phase 2 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | May 2003 | May 8, 2019 |
- OrphaNumber from OrphaNet (Orphanet)
- 86836